Startups
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.
George Chen left AstraZeneca after seven years to pursue his own line of oncology and immunology R&D.
Two new companies exploded onto the scene this morning, backed by significant financing that will be used to develop treatments for a wide range of diseases.
Special purpose acquisition companies (SPACs) are resurging as a virtually hassle-free alternative to initial public offerings (IPOs). They’ve been around for years, but are just now becoming a factor for biotech.
ATAI Life Sciences announced on Monday that it has launched EmpathBio, a wholly-owned subsidiary focused on developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder.
With $46 million in Series A financing, Cambridge, Mass.-based Q32 Bio, with a focus on healthy immune regulation, has emerged onto the scene with plans to enter its lead asset into the clinic later this year.
The new company is focused on tapping into the powers of the immune system to address numerous diseases.
The company will be helmed by Jes Olesen, the former president of the European Federation of Neurological Societies and chairman of the Danish Headache Center.
Each year, BioSpace evaluates biotech startups for the last year and applies an algorithm that includes funding, collaboration, the state of their pipeline and editorial awards for innovation.
Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.
PRESS RELEASES